H&H Group delivers revenue growth across all three business segments for 2022 and expects positive outlook for 2023

• Reported revenue growth of 10.6% with revenue of RMB12,775.9 million and adjusted EBITDA growth of 6.5% despite significant headwinds • Baby Nutrition and Care segment returned to growth (+1.1% on a like-for-like basis), turnaround of the probiotics business and stabilising the infant milk formula (IMF) business in mainland China • Adult Nutrition and Care segment achieved robust growth of 12.5%, with Swisse continuing to be the no.1 player in mainland China’s online VHMS